



Current as of November 7, 2025

#

There were no keywords in this range.

| ٨ | |
|------------------|--|
| \boldsymbol{h} | |

| accelerated aging | A025 |
|---|------|
| Actinium 225/ lutetium177 FAPi therapy, | A013 |
| adiposity | C032 |
| Advanced medullary carcinoma thyroid, | A013 |
| Afferent loop syndrome | A036 |
| Alcohol consumption | C027 |
| Anaplastic Wilms tumors | B002 |
| anus | B017 |
| APC mutation | C005 |
| appendix | B017 |
| | |

B

| B7H3 | C034 |
|--------------------------|------------------|
| basal cell carcinoma | B015 |
| Biomarker | A034 |
| Biomarkers | B029, C011 |
| Biorepository | B004 |
| Birth weight | C006 |
| blistering sunburns | B015 |
| Botswana | B012 |
| Brain immune interaction | C036 |
| breast cancer | A004, A026, B011 |
| Breast cancer screening | A029 |
| Breast IDC, FDG PET/CT | A014 |

\mathbf{C}

| CA-125 | A010 |
|--------|------|
| cancer | C003 |

American Association for Cancer Research® Special Conference in Cancer Research





| Cancer Neuroimmunology | C036 |
|--|------------------------------|
| cancer related anticoagulation | A009 |
| cancer surge | A001 |
| cardiac spheroid | A021 |
| Cardio-Oncology | A021 |
| case report | A019 |
| Case report | A035 |
| Castleman | A035 |
| Cell-free DNA, Early-onset cancer, Liquid biopsy | A023 |
| Cervical cancer | B033 |
| chemoradiation | C026 |
| Chemosensitization | A006 |
| clinical and epidemiological features | B007 |
| Clinical sequencing | B005 |
| clinical trials | A003 |
| clinico-pathological factors | A014 |
| cohort effects; period effects | A011 |
| colibactin | C021 |
| Colon Cancer | C007 |
| colonic polyps | C020 |
| Colorectal | A032 |
| colorectal adenoma | A025 |
| colorectal adenomas | A024 |
| colorectal cancer | B021, B038, C002, C013, C020 |
| Colorectal cancer | B006, C005, C027, C037 |
| Colorectal Cancer | B003, B029, C012, C016 |
| colorectal cancer | C032 |
| Colorectal Cancer Screening, Puerto Rico, Policy | A018 |
| Colorectal cancer; Molecular subtypes; NSAIDs | B036 |
| colorectum | B017 |
| Comorbidities | B029 |
| Contextualised Guidelines | A017 |
| CRC | A027 |





| ı | \mathbf{r} |
|---|--------------|
| н | , |
| - | |

| deep learning, artificial intelligence, machine learning | A012 |
|--|--------------------------------------|
| Demographics and Rurality | B034 |
| DEPICT HEALTH | A015 |
| developmental programming | C035 |
| diagnostic testing | A011 |
| diet | B008 |
| Dietary supplements | B023 |
| Digital health intervention | A008 |
| discontinuation | A003 |
| disease and medication history | B026 |
| disease modeling; natural history | A011 |
| Disparities | B024, B028 |
| DNA methylation | A031 |
| T | |
| E | D012 |
| Earl onset breast cancer | B012 |
| Early Forly detection | C010 A034 |
| Early detection | B006 |
| Early Onset | |
| Early Onset | C007 |
| Early Onset Cancer | C027 |
| Early Onset Cancer | A032, C036 A030 |
| early onset cancer diagnostics | A030 A017 |
| Early onset calcrectal concer | |
| early onset Coloractal Canaar | A022, A024, A025, B010, C030 C029 |
| Early Onset Colorectal Cancer Early Onset CRC | C029 |
| Early onset, Epidemiology, Colorectal Cancer, Puerto | A018 |
| Rico, Policy | A016 |
| early-life antibiotics | C019 |
| Early-onset | A010, B031 |
| Early-onset | C013 |
| Early-onset breast cancer | B014, C008 |





| Early-onset cancer | C017 |
|---|------------------------------------|
| Early-onset cancer survivorship | A008 |
| Early-Onset Cancer, Head and Neck Neoplasms, Survival Analysis | B027 |
| Early-onset cancer, second primary cancer, SEER | B022 |
| early-onset colorectal cancer | B008, B016, B020, C019, C024 |
| Early-onset colorectal cancer | A031, B005, B023, C006, C009, C011 |
| Early-Onset colorectal cancer | A033, B034, B035 |
| Early-Onset Colorectal Cancer | B024 |
| Early-onset gastric cancer | B009 |
| early-onset gastrointestinal cancer | B013 |
| early-onset pancreatic cancer | B026 |
| early-onset prostate cancer | B007 |
| endometrial cancer | A004 |
| Endometrial cancer mutation | C025 |
| environmental etiology | C014 |
| environmental exposures | C023 |
| EOCRC | A016, A027, C001 |
| epidemiology | B013, B019 |
| Epithelial-mesenchymal transition | C002 |
| Etiology | C006 |
| evexomostat | C031 |
| Exogenous risk factors | C017 |
| Exposome | C016 |
| Extrahepatic cholangiocarcinoma | A036 |
| F | |
| familial colorectal cancer | C014 |
| fast food | B008 |
| fatigue | B038 |
| FIT | A032 |
| Fructose | C037 |

\mathbf{G}

American Association for Cancer Research® Special Conference in Cancer Research





| Gallbladder cancer; Arsenic; Risk factor | C018 |
|---|--------------------------------------|
| Gallium FAPI PET/CT, biochemical response | A013 |
| gastric cancer | A012 |
| Gastric cancer | A002, A007, B031 |
| gene expression | C032 |
| Genetic predisposition | C008 |
| genetic risk; carcinogens; cancer predisposition; environment | A028 |
| genomic | C015 |
| Genomic Alterations | C007 |
| Genomic profiling | B005 |
| Genomics | A002 |
| Germline mutations | B009 |
| germline testing | B025 |
| Ghana | B006 |
| global convening | B010 |
| global early onset colorectal cancer research strategy | B010 |
| GSK3β | C028 |
| Н | |
| heavy metals | C018 |
| Hepatobiliary surgery | A036 |
| Hereditary cancers | A016 |
| high fat enviroment | C030 |
| | 6050 |
| hiPSC | A021 |
| | |
| hiPSC | A021 |
| hiPSC Hispanic | A021 C024 |
| hiPSC Hispanic Hispanic populations | A021 C024 |
| hiPSC Hispanic Hispanic populations I | A021 C024 A033 |
| hiPSC Hispanic Hispanic populations I imaging | A021 C024 A033 |
| hiPSC Hispanic Hispanic populations I imaging immune profiling | A021 C024 A033 A026 C013 |





| Implementation Science | B001 |
|--|------------|
| Incidence trends | B022 |
| Intervention Adaption | B001 |
| ISCs | C035 |
| | |
| J | |
| There were no keywords in this range. | |
| K | |
| KDM3C | C010 |
| KRAS | C028 |
| | |
| \mathbf{L} | |
| large-scale registries | B026 |
| Leptin | C034 |
| liquid biopsy | A030 |
| LMIC | B012 |
| LOCRC | A027 |
| Low- and middle-income countries (LMICs) | A017 |
| Lymph nodes | C026 |
| Lynch Syndrome | A016 |
| M | |
| Machine learning | B028 |
| MDM2-MDMX protein | A001 |
| Medications | B023 |
| melanoma | A003 |
| metabolomics | B038, C003 |
| Metabolomics | C009 |
| METAP2 | C031 |
| Metastatic | B003, B031 |
| Methylation | C016 |
| Mexican Teachers' Cohort | B014 |
| Mexico | B020 |





| microbiome | C019 |
|------------------------------|------------------|
| Military cohort | C023 |
| Military Exposure | B018 |
| molecular drivers | C021 |
| mortality | B016, B020 |
| mutational signatures | C015, C020, C021 |
| Mutational signatures | C014 |
| myeloproliferative neoplasms | C003 |
| N | |
| N-acetylneuraminic acid | C037 |
| Needs Assessment | B001 |
| Nociceptors | A007 |
| northeast India | C018 |
| NSCLC | A030 |
| 0 | |
| obesity | B032 |
| Obesity | B035, C031 |
| obesity-associated cancers | B030 |
| Oncogenic-immune dynamics | B002 |
| onset age (early vs. late) | B021 |
| Oral bacteria | A020 |
| organoids | C030 |
| Outcome of treatment | B033 |
| ovarian cancer | B019 |
| Ovarian cancer | A010 |
| Ovarian Cancer Disparity | B018 |
| overall survival | B021 |
| P | |
| Pancraetic cancer | C028 |
| Pancreatic carcinogenesis | C017 |
| Paraneoplastic | A035 |





| particulate matter | B011 |
|----------------------------------|-------------|
| pathogenic variants | A029 |
| Pathway analyses | C033 |
| Patient-Reported Outcomes | B024 |
| PDAC ATM BRCA1/2 | A009 |
| PE DVT DOAC | A009 |
| policy | A004 |
| pollution | B011 |
| Polymorphism | C010 |
| postpartum | B037 |
| Precision oncology | A006 |
| pregnancy | B037 |
| pregnancy and breastfeeding | A029 |
| pregnancy-associated cancer | B037 |
| prevention | A028 |
| primary cardiac leiomyosarcoma | A019 |
| propensity-match | A015 |
| Psychosocial support | A008 |
| Puerto Rican Hispanic/Latino men | B007 |
| Puerto Rico | B030 |
| Q | |
| quantitative FIT | A022 |
| R | |
| red flag symptoms | A022 |
| Race/Ethnicity | B035 |
| racial/ethnic disparities | B016 |
| Radiomics | B002 |
| RAMP1 | A007 |
| rates | B032 |
| rectal cancer | A005., C026 |
| Rectal Cancer | A020 |
| Registry | B004 |
| | |





| Reproductive and post menopausal women Reproductive risk factors Reproductive timing Retinoblastoma Retinoic Acid Signaling risk factors | B033 C008 B014 A015 C004 A033, B013, B019 |
|--|---|
| Risk Factors risk prediction Risk prediction | B003 A024 A034 |
| S survival analysis Sex differences Sex Differences single-nucleus RNA-seq Social determinants of health soft tissue sarcoma somatic mutation Somatic mutations spatial transcriptomics squamous cell carcinoma Survival Outcomes survivorship | A012 C001 C012 C002 B028 A019 C024 B009 A005. B015 C001 |
| T tumor asphericity, Progression free survival Targeted anticancer design temporal trends Timeliness of Treatment Tissue renewal Tissue Renewal toxicities | A014 A001 B030 B034 C005 C004 |
| Transcriptomics Transcriptomics | C033 C029 |





| trends | B032 |
|---------------------------------------|--------------|
| Tumor interception | A006 |
| Tumor Microbiome | A020 |
| Tumor Progression | C034 |
| Tumor stage and location | A031 |
| tumoral microbiome | A005. |
| | |
| U | |
| underserved patients | B025 |
| | |
| \mathbf{V} | |
| Veterans Health | B018 |
| Visceral Adipose Tissue | C029 |
| | |
| W | |
| There were no keywords in this range. | |
| V 7 | |
| X | |
| There were no keywords in this range. | |
| Y | |
| young onset GI cancers | B025 |
| young onset of cancers | D 023 |

\mathbf{Z}

There were no keywords in this range.

Young-onset colorectal cancer

American Association for Cancer Research® Special Conference in Cancer Research

THE RISE IN EARLY ONSET CANCERS – KNOWLEDGE GAPS AND RESEARCH OPPORTUNITIES

B004